Drug Trial Radar · NCT07867938
A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
158
Planned (sponsor's estimate)
Start
Nov 3, 2026
Primary completion
Oct 5, 2029
Study completion Jan 11, 2030
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS). This trial will help researchers learn if a trial medicine called tulisokibart can treat symptoms of active PS. The goal of this trial is to learn if tulisokibart works better than placebo to increase the length of time until PS gets worse.
Conditions
- Pulmonary Sarcoidosis
Interventions
TulisokibartDrug
Subcutaneous (SC) administration
PlaceboOther
SC administration
Background prednisone therapyDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Worsening of Pulmonary Sarcoidosis (PS)Time frame: Up to approximately 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Care Access Research Llc ( Site 2725)
Shreveport, Louisiana · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.